A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer (CSC)
Neoplasms,Colorectal
About this trial
This is an interventional treatment trial for Neoplasms,Colorectal
Eligibility Criteria
Inclusion Criteria:
- Age:18 and over
- Performance status:Karnofsky 70-100%
- Life expectancy:Greater than 6 months
- Hematopoietic:Absolute neutrophil count at least 1000/mm 3,Hemoglobin at least 9 g/dL,Platelet count at least 100,000/mm^3
- Hepatic:Bilirubin less than 2.0 mg/dL No chronic or acute hepatic disease Renal:Creatinine less than 2.5 mg/dL
Cardiovascular:
No chronic or acute cardiac disease (New York Heart Association class III or IV)
- Pulmonary:
No chronic or acute pulmonary illness such as asthma or chronic obstructive pulmonary disease
Exclusion Criteria:
- Patients receiving anticoagulation therapy.
- Patients receiving any other investigational agents.
- Patients who test positive for Hepatitis B virus, Hepatitis C virus or HIV. 4、level 3 hypertension; 5、severe coronary disease; 6、 myelosuppression; 7、 respiratory disease; 8、 brain metastasis; 9、 chronic infections
Sites / Locations
- Biological treatment center in Fuda cancer hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Placebo Comparator
Experimental
Experimental
Experimental
non-cancer stem cell vaccine
giving low dose vaccine
giving middle dose vaccine
giving high dose vaccine
This is no cancer stem cells vaccine in this group
The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.